Serum Methionine Metabolites Are Risk Factors for Metastatic Prostate Cancer Progression

Sally Stabler, Tatsuki Koyama, Zhiguo Zhao, Magaly Martinez-Ferrer, Robert H. Allen, Zigmund Luka, Lioudmila V. Loukachevitch, Peter E. Clark, Conrad Wagner, Neil A. Bhowmick

1 Department of Medicine, University of Colorado, Aurora, Colorado, United States of America, 2 Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, United States of America, 3 Department of Surgery, University of Puerto Rico, San Juan, Puerto Rico, 4 Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, United States of America, 5 Department Urologic Surgery, Vanderbilt University, Nashville, Tennessee, United States of America, 6 Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, United States of America

Abstract

**Background:** Clinical decision for primary treatment for prostate cancer is dictated by variables with insufficient specificity. Early detection of prostate cancer likely to develop rapid recurrence could support neo-adjuvant therapeutics and adjuvant options prior to frank biochemical recurrence. This study compared markers in serum and urine of patients with rapidly recurrent prostate cancer to recurrence-free patients after radical prostatectomy. Based on previous identification of urinary sarcosine as a metastatic marker, we tested whether methionine metabolites in urine and serum could serve as pre-surgical markers for aggressive disease.

**Methodology/Principal Findings:** Urine and serum samples (n = 54 and 58, respectively), collected at the time of prostatectomy were divided into subjects who developed biochemical recurrence within 2 years and those who remained recurrence-free after 5 years. Multiple methionine metabolites were measured in urine and serum by GC-MS. The role of serum metabolites and clinical variables (biopsy Gleason grade, clinical stage, serum prostate specific antigen [PSA]) on biochemical recurrence prediction were evaluated. Urinary sarcosine and cysteine levels were significantly higher (p = 0.03 and p = 0.007 respectively) in the recurrent group. However, in serum, concentrations of homocysteine (p = 0.003), cystathionine (p = 0.007) and cysteine (p < 0.001) were more abundant in the recurrent population. The inclusion of serum cysteine to a model with PSA and biopsy Gleason grade improved prediction over the clinical variables alone (p < 0.001).

**Conclusions:** Higher serum homocysteine, cystathionine, and cysteine concentrations independently predicted risk of early biochemical recurrence and aggressiveness of disease in a nested case control study. The methionine metabolites further supplemented known clinical variables to provide superior sensitivity and specificity in multivariable prediction models for rapid biochemical recurrence following prostatectomy.

Introduction

Prostate cancer remains the most common non-cutaneous solid malignancy in the United States, and the second leading cause of cancer specific death in men. Nevertheless, it has become increasingly clear that not all men who are diagnosed with prostate cancer require intervention [1]. Yet, many men that receive surgical or radiation-based primary treatment develop recurrent disease. Prior to surgical intervention, serum PSA, biopsy Gleason grade, and clinical stage help determine if patients are likely to recur versus those that may remain localized and possibly remain clinically inconsequential. Various approaches in improving the role of PSA in early prostate cancer detection have been tested, but their benefit to overall survival is yet to be proven [2,3]. Ultimately, there is a subgroup of men without conventional negative factors harboring high risk, aggressive disease and are even at elevated risk of early recurrence after attempted definitive local therapy [4,5,6]. The ongoing challenge facing clinicians is how to identify this cohort of men at high risk, from the larger cohort of men who are likely harboring more indolent disease [7]. New markers of aggressive disease are therefore needed for an informed clinical decision.

A previous study identified sarcosine (N-methylglycine) as a product of methionine catabolism that is elevated in the urine of patients with metastatic prostate disease [8]. Sarcosine levels were higher in tissues from localized prostate cancer than in normal tissue, and even higher in metastatic prostate tissue. Urinary sarcosine was thus suggested as a possible marker for metastatic prostate cancer. The enzyme, Glycine N-methyltransferase (GNMT) is the primary source of sarcosine in liver, where it accounts for about 1% of the soluble protein [9]. Individuals with defective sarcosine dehydrogenase have sarcosinemia, but show no distinctive phenotype [10]. However, a reported causative role for sarcosine in prostate cancer metastasis [8], suggests therapeutic targeting of its metabolic pathway to be useful.
In this study we evaluated the serum and urine of radical prostatectomy patients for metabolites to differentiate those who developed early biochemical recurrence (rise in serum PSA≥0.2 ng/ml) within two years of surgery and those who remained recurrence-free after more than five years. We found that the urine of patients in the rapidly recurrent group had significantly higher concentrations of sarcosine and cysteine than those in the recurrence-free group. In addition, significantly greater concentrations of serum cystathionine, homocysteine and cysteine were found in the rapidly recurrence group compared to the recurrence-free group. These products of elevated methionine catabolism in patients with rapidly recurrent prostate cancer represent pre-surgical indicators that augmented serum PSA for the prediction of clinically significant prostate cancer.

**Methods**

**Ethics Statement**

This nested case-control study was conducted in accordance with the Institutional Review Board of Vanderbilt University. Written consent was given by the patients for their information to be stored in the hospital database. The board specifically approved the research use of the de-identified information and “on the shelf” specimens to be used for research under a waiver of consent.

**Patient selection**

The digital medical records of 400 subjects were retrospectively examined using the Vanderbilt University Department of Urologic Surgery registry of radical prostatectomies performed between 2003 and 2007. Several patients were excluded for reasons of compromised renal, heart, or liver function as was determined by electronic records of elevated urinarin creatinine, hypertension, cardiac infarction history, and blood markers for hepatic function. Additionally, availability of follow-up data and records of pre-surgical hormone-ablation therapy were reasons for exclusion. Rapidly recurrent patients were identified as those who developed biochemical recurrence following prostatectomy within 2 years (American Joint Committee on Cancer defined as having PSA≥0.2 ng/ml, confirmed at least once two weeks later). The recurrence-free population was defined as having maintained a serum PSA<0.01 ng/ml for five or more years following surgery. Ultimately, for this nested case control study we focused on 54 subjects for analysis of urine and 58 subjects for analysis of serum who developed rapid biochemical recurrence and an age-matched recurrence-free control group who were free of recurrence. The mean age for the subjects was 60 years. All subjects were annotated based on age, pre-surgical serum PSA, biopsy Gleason score, clinical stage, and detection of biochemical recurrence.

**Urine and Serum Quantitative Metabolic Analysis**

Serum and urine obtained at the time of radical prostatectomy were rapidly processed and stored at −80°C. We evaluated serum and urine for the metabolites, sarcosine, dimethylglycine, methionine, homocysteine, cystathionine, cysteine, methylmalonic acid and methylcitrate by gas-liquid chromatography/mass spectrometry [11,12,13]. Folate was measured microbiologically as described by Horne [14]. Urinary metabolites were expressed as nmol/mg creatinine to correct for differences in urine volume. Creatinine in urine was measured by the Jaffe method [15].

**Statistical Analysis**

 Patients’ baseline demographic and clinical variables were assessed using Wilcoxon rank sum tests for continuous variables and Fisher exact tests for categorical (including binary) variables. All marker values, as well as PSA levels, were logarithmically transformed to achieve normality. Correlations among the markers were assessed using Spearman’s rank correlation. Logistic regression models were used to analyze incidence of recurrence. The base model includes serum PSA, biopsy Gleason score, and clinical stage, clinical variables that are available prior to surgery. The post-surgical variables (e.g., lymph nodes, surgical margins, pathologic Gleason scores) were not considered. For multiplicity control, p≤0.007 (p-value less than 5%/7 = 0.7%) was considered statistically significant. To avoid further overfitting of the data, no variable selection was performed in the subsequent analyses based on logistic regression models. We used a likelihood ratio test to compare the simpler model (without the metabolites) and the full model (with the individual metabolites). Receiver operating characteristics (ROC) curves were generated for each logistic regression model, where the area under ROC curve (AUC) was determined. Integrated discrimination improvement (IDI) and Net reclassification index (NRI) [16] were used to compare the models’ ability to distinguish recurrence and non-recurrence. The logrank tests were used to assess the difference in recurrence-free survival between the two groups illustrated by Kaplan-Meier plots. For the selected markers, Cox proportional hazard regression models were fit, and likelihood ratio tests were used to assess markers’ association with time to recurrence outcome. The proportional hazard assumption was assessed using the method of Grambsch and Therneau [17]. All data analyses were performed using R 2.10.1 (R Development Core Team, Vienna, Austria); a

**Table 1.** The values for methionine metabolites measured in the urine of the recurrent-free and the recurrent groups are compared.

|                    | Recurrent-free (29) | Recurrent (25) | P value  |
|--------------------|---------------------|----------------|----------|
| **Age**            |                     |                |          |
|                     | 59 (53, 64)         | 62 (58, 67)    | 0.10     |
| **Pre-surgery PSA**|                     |                |          |
|                     | 5.2 (4.3, 6.5)      | 6.0 (5.0, 8.2) | 0.08     |
| **Clinical stage** | (N = 16/18)         |                | 0.09     |
| **T1**             | 15 (94%)            | 12 (67%)       |          |
| **T2**             | 1 (6%)              | 6 (33%)        |          |
| **T3**             | 0                   | 0              |          |
| **Biopsy Gleason** | (N = 16/18)         |                | 0.050    |
|                    | 4                   | 0              |          |
|                    | 5                   | 2 (12%)        | 0        |
|                    | 6                   | 9 (56%)        | 4 (22%)  |
|                    | 7                   | 3 (19%)        | 8 (44%)  |
|                    | 8                   | 1 (6%)         | 3 (17%)  |
|                    | 9                   | 0              | 2 (11%)  |
|                    | 10                  | 0              | 1 (6%)   |
| **Urine cysteine** | (N = 29/24)         |                | 0.007    |
|                    | 190 (168, 212)      | 221 (189, 252) |          |
| **Urine homocysteine** |            |                | 0.40     |
|                    | 2.7 (2.2, 3.2)      | 2.8 (2.4, 4.0) |          |
| **Urine dimethylglycine** |          |                | 0.34     |
|                    | 27.3 (22.1, 38.5)   | 25.4 (17.6, 33.7) |       |
| **Urine sarcosine** | 3.7 (3.1, 5.7)      | 5.4 (4.1, 6.7) | 0.03     |

Values for sarcosine, homocysteine, dimethylglycine and cysteine are expressed as μmole/mg creatinine. Wilcoxon rank sum tests for continuous variables and Fisher exact tests for categorical (including binary) variables are indicated. Normal values for metabolites (nmole/mg creatinine) are: cysteine, 10–157; homocysteine, 0.974–7.17; dimethylglycine, 10.1–108.2 and sarcosine, 2.65–8.67. Median values with quartiles were used to summarize the distributions of the continuous variables.

https://doi.org/10.1371/journal.pone.0022486.t001
significance level of 0.05 was used for statistical inference unless otherwise noted.

Results

Methionine metabolites support prediction of biochemical recurrence

Urine metabolites were initially measured in fifty-four patients who developed biochemical recurrence (N = 25) and those that remained recurrence-free (N = 29). These patients were matched for age and pre-surgical serum PSA. Table 1 enumerates the clinical characteristics of the two patient groups by serum PSA, clinical stage, and biopsy Gleason grade. Majority of patients had a clinical stage of T1. Creatinine-normalized urinary dimethylglycine-normalized urinary dimethylglycine-

Table 2. The values for methionine metabolites measured in the sera of the recurrent-free and the recurrent groups are compared.

|                  | Recurrent-free (30) | Recurrent>(28) | P value |
|------------------|---------------------|----------------|---------|
| Age              | 59 (54, 64)         | 61 (59, 64)    | 0.07    |
| Pre-surgery PSA  | 5.4 (4.0, 8.1)      | 6.8 (5.2, 8.9) | 0.02    |
| Clinical stage   |                     |                | 0.30    |
| T1               | 24 (80%)            | 18 (64%)       |         |
| T2               | 6 (20%)             | 9 (32%)        |         |
| T3               | 0                   | 1 (4%)         |         |
| Biopsy Gleason   |                     |                | 0.006   |
| 4                | 1 (3%)              | 0              |         |
| 5                | 2 (7%)              | 0              |         |
| 6                | 18 (60%)            | 6 (20%)        |         |
| 7                | 6 (20%)             | 13 (46%)       |         |
| 8                | 2 (7%)              | 4 (15%)        |         |
| 9                | 1 (3%)              | 4 (15%)        |         |
| 10               | 0                   | 1 (4%)         |         |
| Serum cysteine   | 346 (321, 377)      | 419 (367, 452) | <0.001  |
| Serum homocysteine| 9.0 (8.0, 10.2)    | 11.7 (9.4, 13.4)| 0.003   |
| Serum dimethylglycine (n = 27/23) | 4.6 (3.8, 4.7) | 4.9 (4.2, 5.4) | 0.21    |
| Serum sarcosine (n = 27/23) | 1.3 (1.1, 1.4) | 1.3 (1.1, 1.7) | 0.67    |
| Serum methionine (n = 27/27) | 24.8 (21.7, 30.6) | 27.6 (23.9, 33.7) | 0.08    |
| Serum folate (n = 27/28) | 44.8 (25.2, 52.8) | 42.3 (31.3, 51.5) | 0.72    |
| Serum methylcitrate | 126 (102, 144) | 135 (117, 167) | 0.13    |
| Serum methylmalonate | 167 (145, 220) | 164 (146, 211) | 0.91    |
| Serum cystathionine (n = 29/26) | 149 (130, 176) | 186 (148, 239) | 0.007   |
| Lymph node involvement | 0 (0%) | 6 (21%) | 0.01    |
| SV involvement    | 0 (0%)              | 8 (29%)        | 0.002   |
| Positive surgical margin | 1 (3%) | 8 (29%) | 0.01    |
| Stage III+        | 3 (10%)             | 21 (75%)       | <0.001  |
| Pathologic Gleason|                     |                | 0.002   |
| 5                | 2 (7%)              | 0 (0%)         |         |
| 6                | 15 (50%)            | 4 (14%)        |         |
| 7                | 10 (33%)            | 14 (50%)       |         |
| 8                | 3 (10%)             | 4 (14%)        |         |
| 9                | 0 (0%)              | 6 (21%)        |         |

Wilcoxon rank sum tests for continuous variables and Fisher exact tests for categorical (including binary) variables are indicated. Normal values for metabolites are: cysteine, 203–369 μM; homocysteine, 5.4–13.9 μM; dimethylglycine, 1.4–5.3 μM; sarcosine, 0.6–2.7 μM; methionine, 11.3–42.7 μM; folate, >3.0 ng/ml; methylcitrate, 60–228 nM; methylmalonate, 73–271 nM; cystathionine, 44–342 nM. Median values with quartiles were used to summarize the distributions of the continuous variables. doi:10.1371/journal.pone.0022486.t002

Table 3. Correlations between serum and urine markers.

|                  | Correlation coefficient | P value | n   |
|------------------|------------------------|---------|-----|
| Sarcosine        | 0.19                   | 0.34    | 28  |
| Dimethylglycine  | 0.12                   | 0.53    | 28  |
| Cysteine         | 0.33                   | 0.06    | 33  |
| Homocysteine     | 0.13                   | 0.48    | 34  |

All correlations are rank based “Spearman’s rho”. doi:10.1371/journal.pone.0022486.t003
cine and homocysteine were not significantly different between the two groups. However, we found urinary sarcosine to be significantly elevated at the time of surgery in patients who developed biochemical recurrence, as originally reported for patients with frank prostate metastatic lesions [8]. We further found that urinary cysteine was significantly elevated in biochem-

![Figure 1. Kaplan-Meier plots indicate univariate predictive values of the recurrence-free survival based on pre-surgical serum.](image)

| Figure 1. Kaplan-Meier plots indicate univariate predictive values of the recurrence-free survival based on pre-surgical serum. The patients were separated into two groups, divided at median tissue level for (A) PSA, (B) homocysteine, (C) cystathionine, and (D) cysteine as significantly associated with time to recurrence (Table 5). Those subjects above the median expression level were termed upper half, whereas those below the median were termed lower half. The recurrence-free survival probabilities were estimated by the Kaplan-Meier method and the differences were tested using the log-rank test. Each of the dichotomous serum markers supported statistically significant differences in biochemical recurrence-free survival.

doi:10.1371/journal.pone.0022486.g001

Table 4. Correlations among serum markers.

|                | Dimethylglycine | Sarcosine        | Cysteine         | Cystathionine  |
|----------------|-----------------|------------------|------------------|----------------|
| Homocysteine   | 0.28, 0.05 n=50 | 0.28, 0.04 n=50  | 0.65, <0.01 n=57 | 0.22, 0.10 n=55 |
| Dimethylglycine | 0.35, 0.01 n=50 | 0.40, <0.01 n=50 | 0.16, 0.26 n=48 |                |
| Sarcosine      | 0.35, <0.01 n=50| 0.35, <0.01 n=50 | 0.08, 0.60 n=48 |                |
| Cysteine       |                 | 0.39, <0.01 n=54 |                  |                |

All correlations are rank based “Spearman’s rho”, presented as correlation, p-value, and n.
doi:10.1371/journal.pone.0022486.t004
ically-recurrent patients compared to those who remained recurrence-free five years following prostatectomy. Urine analysis in a pre-surgical patient population suggested products of methionine catabolism might correlate with prostate cancer progression status.

We then performed a nested case control study with pre-surgical serum. Fifty-eight age-matched prostatectomy patients were stratified by pre-surgical PSA, clinical stage, and biopsy Gleason grade as well as pathologic variables (Table 2). As expected, clinical variables were significantly different in the two populations, as were the post-surgical pathologic factors. Interestingly, the serum homocysteine, cystathionine, and cysteine were significantly higher in the biochemically-recurrent patients (p value < 0.001). However, clinical stage and serum levels of sarcosine, dimethylglycine, folate, methylcitrate, and methylmalonic acid were not significantly different between the two populations. Normal methylcitrate levels in both populations supported renal sufficiency. Serum methylmalonic acid levels, an indicator of vitamin B-12 status [18], were not different between the two groups. Serum and urine cysteine correlation did not reach statistical significance (p = 0.06, Table 3). However, serum homocysteine was strongly correlated with cysteine (Spearman’s rank correlation = 0.65, p<0.01). Therefore, the higher serum homocysteine was not a function of differences in renal function, vitamin B-12 or folate status.

The relevance of these newly identified markers to patient recurrence status were illustrated in Kaplan-Meier plots for homocysteine, cystathionine, and cysteine as compared to pre-operative serum PSA levels, and time-to-recurrence (Figure 1). Each of the markers could separate rapidly recurrent from the recurrence-free progression. However, serum cysteine detection had the greatest discriminatory power in the two populations prior to prostatectomy.

The clinical value of these methionine metabolites as biomarkers would be to significantly increase the ability to predict aggressive prostate cancer features and early biochemical recurrence over and above existent clinical variables including serum PSA, biopsy Gleason score, and clinical stage. We developed a multiple logistic regression model for the prediction of biochemical recurrence based on serum methionine metabolites and the pre-surgical predictor variables, serum PSA and biopsy Gleason grade. Since majority of patients in both cohorts had clinical stage T1c disease, this variable had little discriminative power and was dropped from the model. Serum cysteine, cystathionine, and homocysteine were the top three predictors for recurrence in 70% of the patients, so further analysis of methionine metabolites focused on these three metabolites. Correlations between cysteine and homocysteine were the highest among all pair-wise correlations (R² = 0.65, p<0.01), and cysteine was also highly correlated with cystathionine (R² = 0.39, p<0.01, Table 4). Addition of serum homocysteine provided the greatest improvement of the logistic regression models compared to the base model with PSA and biopsy Gleason (p = 0.0007), followed by cysteine (p = 0.0017), and cystathionine (p = 0.0037). Correlation

Table 5. Logistic regression models.

| Variable          | Comparison Q3:Q1 | Odds     | 95% Confidence Int. | P value |
|-------------------|------------------|----------|---------------------|---------|
| Pre-surgery PSA   | 8.5 : 4.7        | 2.39     | (0.90, 6.33)        | 0.080   |
| Biopsy GS        | 7 : 6            | 4.29     | (1.59, 11.56)       | 0.004   |
| Serum homocysteine| 12.5 : 8.6       | 4.74     | (1.61, 13.90)       | 0.005   |

SERUM CYSTATHIONINE MODEL

| Variable          | Comparison Q3:Q1 | Odds     | 95% Confidence Int. | P value |
|-------------------|------------------|----------|---------------------|---------|
| Pre-surgery PSA   | 8.5 : 4.7        | 2.94     | (1.02, 8.48)        | 0.046   |
| Biopsy GS        | 7 : 6            | 2.80     | (1.24, 6.28)        | 0.013   |
| Serum cystathionine| 200 : 139        | 2.44     | (1.07, 5.56)        | 0.033   |

SERUM CYSTEINE MODEL

| Variable          | Comparison Q3:Q1 | Odds     | 95% Confidence Int. | P value |
|-------------------|------------------|----------|---------------------|---------|
| Pre-surgery PSA   | 8.5 : 4.7        | 1.82     | (0.66, 4.96)        | 0.245   |
| Biopsy GS        | 7 : 6            | 2.51     | (1.19, 5.31)        | 0.015   |
| Serum cysteine   | 436 : 343        | 5.79     | (1.65, 20.29)       | 0.006   |

Table 6. The Integrated Discrimination Improvement (IDI) and Net Reclassification Improvement (NRI) were summarized below, supporting the statistical significance of the improvement.

|          | IDI  | 95% CI       | P-value | NRI  | 95% CI       | P-value |
|----------|------|--------------|---------|------|--------------|---------|
| Homocysteine | 0.14 | 0.05–0.24    | 0.003   | 1.03 | 0.52–1.55    | <0.001  |
| Cystathionine | 0.12 | 0.004–0.20   | 0.003   | 0.81 | 0.28–1.34    | 0.003   |
| Cysteine  | 0.14 | 0.04–0.23    | 0.005   | 0.64 | 0.13–1.16    | 0.015   |

doi:10.1371/journal.pone.0022486.t005
doi:10.1371/journal.pone.0022486.t006
Specifically, serum cysteine, cystathionine, and homocysteine compared to a combined prediction of biochemical recurrence by PSA test is evident when PSA sensitivity and specificity were supported the statistical significance of the improvement (IDI) and Net Reclassification Improvement (NRI) variables alone (AUC = 0.81). The Integrated Discrimination Improvement for the cysteine, cystathionine, and homocysteine when combined with the clinical variables and significantly superior to the clinical models. Area under the ROC curves were similar (AUC = 0.86) for the cysteine, cystathionine, or homocysteine in addition to serum PSA levels and biopsy Gleason grade were compared to a model utilizing PSA plus biopsy Gleason only. Clinical stage values did not contribute to the improvement of the models. Area under the ROC curves were similar (AUC = 0.86) for the cysteine, cystathionine, and homocysteine when combined with the clinical variables and significantly superior to the clinical variables alone (AUC = 0.81). The Integrated Discrimination Improvement (IDI) and Net Reclassification Improvement (NRI) supported the statistical significance of the improvement (Table 6). The benefit of these metabolites as combined with the standard PSA test is evident when PSA sensitivity and specificity were compared to a combined prediction of biochemical recurrence by the ROC in Figure 2 following prostatectomy, using only serum PSA. The AUC with only serum markers were similar to the more comprehensive ones including biopsy results. There was a significant association between these markers and recurrence status, however the markers did not necessarily indicate usefulness in predicting recurrence-free survival.

To define the efficacy of the markers in predicting recurrence-free survival, Cox proportional hazard regression models were fit showing that cysteine, cystathionine, and homocysteine were each independent predictors of recurrence-free survival when adjusting for pre-operative serum PSA and biopsy Gleason score (Table 7). Specifically, serum cysteine, cystathionine, and homocysteine values increased (p<0.001, p = 0.014, p<0.001, respectively) with increased risk of recurrence on multivariable analysis with adjustment for both serum PSA and biopsy Gleason score.

Discussion

Current risk stratification of patients prior to surgery involves variables including serum PSA, clinical stage, and biopsy grade. Independent serum markers in conjunction with PSA could help distinguish patients with aggressive prostate cancer. In the current era of PSA testing, clinical staging has reduced relevance when tumor volumes are relatively small. In our study, the highest biopsy Gleason score in ≥8-core biopsies provided a significant independent predictor comparable to serum cysteine and homocysteine. However, routine ultrasound directed first biopsies are reported to miss nearly a quarter of the prostate cancers [19] and often underestimate tumor grade [20,21]. The combination of serum PSA with cystathionine, cysteine, and homocysteine as markers could improve decision-making for primary treatment and earlier subsequent adjuvant therapy.

Pathways of methionine metabolism involve two mechanisms for sarcosine formation [Figure 3]. Cystathionine and cysteine are products of homocysteine catabolism important in production of glutathione. Elevation of urinary sarcosine in the absence of serum sarcosine differences was surprising, and likely the result of differential renal sarcosine excretion. Changes in sarcosine but not dimethylglycine suggest that increased activity of GNMT might have been present in the recurrent group. It is possible that for unknown reasons the recurrent group had increased S-adenosyl-methionine (SAM) which activated the transulfuration pathway [22] thus, increasing cystathionine, cysteine, and formation of sarcosine. It should be noted that Sreekumar et al. [8] did not report sarcosine in patient serum or plasma associated with metastatic prostate cancer. Our data in pre-surgical subjects supports the previous report of urinary sarcosine elevation in confirmed metastatic patients. The data could mean that our patient population had previously undetected metastasis or that the elevated methionine metabolism is a precursor for metastasis. The direct role of sarcosine on metastatic progression is controversial. In contrast to the report of sarcosine directly supporting metastasis [8], a recent report suggests no association between urinary sarcosine levels and either tumor stage or Gleason
It is difficult to compare our findings with others since the initial study by Sreekumar et al [8] differ in the methodology of sarcosine measurement [24], sample source [25,26], and importantly criteria defining recurrence [23–27]. Our assay utilizes a stable isotope internal standard in each sample, retrieved urine and serum prior to prostate resection, and recurrence was only based on serum PSA detection. Another study compared benign controls against patients with active prostate cancer and found that urine sarcosine was only a modest predictor of disease, but when added to other new markers such as prostate

**Table 7.** Cox regression models.

| Variable                  | Comparison Q3:Q1 | Hazard   | 95% Confidence Int. | P value |
|---------------------------|------------------|----------|---------------------|---------|
| **SERUM HOMOCYSTEINE MODEL** |                  |          |                     |         |
| Pre-surgery PSA           | 8.5 : 4.7        | 2.34     | (1.27, 4.32)        | 0.007   |
| Biopsy GS                 | 7 : 6            | 2.01     | (1.44, 2.79)        | <0.001  |
| Serum homocysteine        | 12.5 : 8.6       | 2.43     | (1.48, 4.01)        | <0.001  |
| **SERUM CYSTATHIONINE MODEL** |                  |          |                     |         |
| Pre-surgery PSA           | 8.5 : 4.7        | 2.47     | (1.30, 4.70)        | 0.006   |
| Biopsy GS                 | 7 : 6            | 1.64     | (1.21, 2.22)        | 0.001   |
| Serum cystathionine       | 200 : 139        | 1.69     | (1.11, 2.57)        | 0.014   |
| **SERUM CYSTEINE MODEL**  |                  |          |                     |         |
| Pre-surgery PSA           | 8.5 : 4.7        | 2.00     | (1.03, 3.86)        | 0.039   |
| Biopsy GS                 | 7 : 6            | 1.71     | (1.24, 2.37)        | 0.001   |
| Serum cysteine            | 436:343          | 2.59     | (1.51, 4.43)        | <0.001  |

Serum Metabolites and Prostate Cancer Recurrence

**Figure 3.** Methionine metabolism. Methionine is first converted to SAM, the donor of methyl groups in all but one methyltransferase reaction. SAM may transfer the methyl group to a variety of compounds, X, by a group of specific enzymes to yield the methylated compounds, CH3-X (e.g. methylated lipids, DNA, or proteins). Alternatively, SAM may transfer the methyl group to glycine to form sarcosine via the enzyme glycine N-methyltransferase (GNMT). After transfer of the methyl group SAM is converted to S-adenosylhomocysteine (SAH), which is broken down further to homocysteine, cystathionine and cysteine. Sarcosine may also be formed by breakdown of choline to betaine, which, after loss of a methyl group, is converted to dimethylglycine. A dehydrogenase converts dimethylglycine to sarcosine.

doi:10.1371/journal.pone.0022486.g003
cancer antigen 3 and percent-free PSA improved diagnostic power [27]. There is abundant evidence that folate and B12 deficiency and kidney disease can contribute to hyperhomocysteinemia. However, in the present investigation there was no difference in folate or methylmalonic acid levels between recurrent and non-recurrent groups. The patients in the current study were accordingly recruited to minimize complicating co-morbidities. The differences we found in homocysteine, cystathionine and cysteine in serum suggest that there may be systemic metabolic differences in those patients who go on to have a biochemical relapse.

The majority of the sarcosine produced in the body is made in the liver as a downstream product of SAM and homocysteine. Studies using homozygous mice with GNMT knocked out have plasma SAM levels 50% greater than that of wild type. The SAM levels in the livers of the Gnut null animals were 33 fold higher than in the livers of wild type animals and all of the Gnut null animals developed hepatocellular carcinoma after 8 months [28]. Interestingly, higher cysteine values are associated with obesity [29–32]. The limited body composition data for our subject groups, however suggested little correlation of body mass index and recurrence rate. The data reported here, support increased flow through GNMT resulting in the increased formation of homocysteine and sarcosine through increased utilization of SAM. Interestingly, GNMT, is reported to be down-regulated in neoplastic tissues in general [33] including human prostate cancer [34]. Thus, the changes seen in the current investigation may not be a result of neoplastic changes in prostate tissue. These results suggest the hypothesis that there may be differences in the methylation capacity of different individuals or tumor hosts as a result of different levels of SAM. Unfortunately, SAM values could not be measured in the current study, because of the instability of SAM in stored serum samples. Further, it is possible that individuals with a greater methylating capacity are more likely to develop cancer leading to metastatic progression.

To our knowledge, no previous study has correlated an entire arm of a metabolic pathway in the aggressiveness of cancer. In our study the comparison was made between patients with proven cancer, not between subjects with proven cancer and benign prostatic disease. These results were obtained with only a relatively small group of patients but the results are significant and suggest that further studies are needed. The underlying biology supports the robustness of these markers. Higher serum homocysteine, cystathionine, and cysteine improved the utility of currently used clinical variables in predicting early recurrence and suggest a greater flux of methyl groups through the enzyme GNMT.

Author Contributions
Conceived and designed the experiments: CW NAB PEC SS. Performed the experiments: SS MM-F RHA LVL ZAL. Analyzed the data: SS TK ZZ. CW NAB. Contributed reagents/materials/analysis tools: NAB TK CW SS. Wrote the paper: NAB CW TK PEC.

References
1. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, et al. (2002) Overdiagnosis to prostate-specific antigen: a non-randomized study of two screening approaches. J Natl Cancer Inst 94: 981–990.
2. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, et al. (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360: 1310–1319.
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320–1328.
4. Thompson IM, Pauker DK, Goodman PJ, Tangen CM, Lucia MS, et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per millilitre. N Engl J Med 350: 2239–2246.
5. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, et al. (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. Jama 294: 66–70.
6. Blum DL, Koyama T, M’Koma AE, Ibarregui JM, Martinez-Ferrer M, et al. (2008) Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res 14: 7970–7977.
7. Thompson KE, Hernandez J, Canby-Hagino ED, Troyer D, Thompson IM (2002) Prognostic features in men who died of prostate cancer. J Urol 174: 553–556, discussion 556.
8. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910–914.
9. Luka Z, Mudd WH, Wagner C (2009) Glycine N-methyltransferase and regulation of S-adenosylmethionine levels. J Biol Chem 284: 22507–22511.
10. Levy HL, Coulombe JT, Benjamin R (1984) Massachusetts Metabolic Disorders Screening Program: III. Sarcosinemia. Pediatrics 74: 1509–1513.
11. Allen RH, Stabler SP, Lindenbaum J (1993) Serum betaine, N,N-dimethylglycine and N,N-dimethylglycine levels in patients with cobalamin and folate deficiency and related inborn errors of metabolism. Metabolism 42: 1480–1460.
12. Allen RH, Stabler SP, Savage DG, Lindenbaum J (1993) Elevation of 2-methylcitric acid I and II levels in serum, urine, and cerebrospinal fluid of patients with cobalamin deficiency. Metabolism 42: 978–988.
13. Stabler SP, Marcell PD, Pollak CC, Allen RH, Savage DG, et al. (1988) Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 81: 466–474.
14. Horne DW, Patterson D (1983) Lactobacillus casei microbiological assay of folate acid derivatives in 96-well microtitre plates. Clinical Chemistry 34: 2357–2359.
15. Barr DB, Wilder LC, Cashdall SP, Gonzalez AJ, Needham LL, et al. (2005) Urinary creatinine concentrations in the U.S. population: implications for urinary biological monitoring measurements. Environ Health Perspect 113: 192–200.
16. Pencina MJ, D’Agostino RB Sr, D’Agostino RB, Jr. (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157–172.
17. Grambsch P, Therneau T (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 315–325.
18. Baik HW, Russell RM (1999) Vitamin B12 deficiency in the elderly. Amn Rev Nutr 19: 357–377.
19. Roehl KA, Antenor JA, Catalona WJ (2002) Serial biopsy results in prostate cancer screening study. J Urol 176: 2433–2439.
20. Capitanio U, Karakiewicz PI, Jeldres C, Briganti A, Gallina A, et al. (2009) The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. Int J Urol 16: 526–529.
21. Beam CA, Gao W, Macias V, Liang W, Balla AK (2009) Sequential testing approach as an efficient and easier alternative for the validation of new predictive technologies in the clinic. J Clin Oncol 27: 1087–1090.
22. Finkelstein JD, Kyle WE, Martin JL, Pick AM (1975) Activation of cystathionine synthase by adenosylmethionine and adenosylmethionine. Biochem Biophys Res Commun 66: 81–87.
23. Jentzmik F, Stephan C, Miller K, Schrader M, Eberhardshofer A, et al. (2010) Sarcosine in urine after digital rectal examination falls as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 58: 12–18; discussion 20–11.
24. Hewavitharana AK (2010) Letter to the editor. Eur Urol 58: e39–e40.
25. Jentzmik F, Stephan C, Lin E, Miller K, Kamlage R, et al. (2011) Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 185: 706–711.
26. Stones EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA (2010) Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem 47: 202.
27. Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX, et al. (2011) Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of differential algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis 14: 166–72.
28. Martinez-Chantar ML, Varquez-Chantada M, Ariz U, Martinez N, Varela M, et al. (2008) Lysine, glutamate, and cystine are not a differential metabolite for prostate cancer. Int J Urol 16: 238–243.
29. Martinez-Chantar ML, Varquez-Chantada M, Ariz U, Martinez N, Varela M, et al. (2008) Lysine, glutamate, and cystine are not a differential metabolite for prostate cancer. Int J Urol 16: 238–243.
30. Stabler SP, Marcell PD, Pollak CC, Allen RH, Savage DG, et al. (1988) Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 81: 466–474.
31. Horne DW, Patterson D (1983) Lactobacillus casei microbiological assay of folate acid derivatives in 96-well microtitre plates. Clinical Chemistry 34: 2357–2359.
32. Barr DB, Wilder LC, Cashdall SP, Gonzalez AJ, Needham LL, et al. (2005) Urinary creatinine concentrations in the U.S. population: implications for urinary biological monitoring measurements. Environ Health Perspect 113: 192–200.
32. Kane CJ, Im R, Amling CL, Presti JC, Jr., Aronson WJ, et al. (2010) Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology 76: 695–700.

33. Heady JE, Kerr SJ (1975) Alteration of glycine N-methyltransferase activity in fetal, adult, and tumor tissues. Cancer Research 35: 640–643.

34. Huang YC, Lee CM, Chen M, Chung MY, Chang YH, et al. (2007) Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin Cancer Res 13: 1412–1420.